Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy by Lonsdale, DO et al.
REVIEW
published: 02 December 2020
doi: 10.3389/fmed.2020.588863
Frontiers in Medicine | www.frontiersin.org 1 December 2020 | Volume 7 | Article 588863
Edited by:
Matteo Bassetti,
University of Genoa, Italy
Reviewed by:
Sunny Oteikwu Ochigbo,
University of Calabar, Nigeria
Mario Venditti,





This article was submitted to
Infectious Diseases - Surveillance,
Prevention and Treatment,
a section of the journal
Frontiers in Medicine
Received: 29 July 2020
Accepted: 02 November 2020
Published: 02 December 2020
Citation:
Lonsdale DO, Shah RV and Lipman J
(2020) Infection, Sepsis and the
Inflammatory Response: Mechanisms
and Therapy. Front. Med. 7:588863.
doi: 10.3389/fmed.2020.588863
Infection, Sepsis and the
Inflammatory Response:
Mechanisms and Therapy
Dagan O. Lonsdale 1,2*, Reya V. Shah 1,2 and Jeffrey Lipman 3,4,5
1Department of Clinical Pharmacology, St George’s University of London, London, United Kingdom, 2Department of Critical
Care, St George’s University Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom,
3Department of Intensive Care, Royal Brisbane and Women’s Hospital, Brisbane, QLD, Australia, 4University of Queensland
Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia, 5Division of Anaesthesiology Critical
Care Emergency and Pain Medicine, NÎmes University Hospital, University of Montpellier, NÎmes, France
Sepsis secondary to bacterial infection remains a significant cause of morbidity and
mortality globally. Recent decades have seen the evolution of international collaborations
to improve care for these patients and identify areas for research. In this article we
discuss the pathophysiology underlying the condition, review the current recommended
management strategies, discuss areas of controversy, and highlight the need for ongoing
research, particularly in diagnostics.
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INTRODUCTION
The global burden of bacterial infection is significant. In the UK, beta-lactams and macrolide
antibiotics account for 25 million prescriptions annually, and global antibiotic prescriptions are
in the billions (1, 2). Associated healthcare costs are considerable, accounting for over $30 billion
(∼8%) of US healthcare spending (3). At the severe end of the spectrum, sepsis is a common reason
for admission to intensive care, accounting for as much as 30% of admissions to adult (4–6) and
12% of admissions to pediatric units (7, 8). Up to 70% of intensive care patients will receive at least
one course of antibiotics during their stay, regardless of age (9, 10). Mortality from severe infection
in adults and children remains as high as 25–30% (8, 11). In neonates, infection remains one of
the most common causes of death worldwide (12–14). Understanding and managing infection is
therefore a core skill for physicians and healthcare professionals. In this article, we will explore the
pathology, diagnosis, and management of infection and sepsis, discuss some of the complexities
and challenges.
INFECTION, SEPSIS, AND THE INFLAMMATORY RESPONSE
The human response to an infection follows recognition of infectious pathogens by
immune cells via pattern recognition receptors. The resulting cellular activation leads to the
production of pro- (particularly IL-1 and TNFα) and anti-inflammatory mediators and the
subsequent recruitment and activation of other immune cells (e.g., polymorphonucleocytes
and B-cells) (15). In the normal host response to infection, equilibrium is reached
between pro- and anti-inflammatory processes, bactericidal activity is maximized, alongside
necessary phagocytosis, and repair of damaged tissue. In sepsis, this equilibrium is lost.
Localized tissue response to infection becomes systemic and the inflammatory process
becomes deleterious in its own right. Sepsis being formally defined as “life-threatening
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organ dysfunction caused by a dysregulated host response to
infection” (16). Effects are seen across organ and tissue types.
Endothelial damage results in loss of normal homeostasis, leading
to fluid leak, and tissue oedema. In the vasculature there is
vasodilatation mediated through several mechanisms such as the
effect of acidosis on vascular smooth muscle, induction of nitric
oxide by inflammatory mediators, and adrenal insufficiency.
The consequent drop in systemic vascular resistance may be
compensated by increased cardiac output or compounded by
myocardial depression–leading to hypotension and reduced
tissue perfusion. In the lungs, fluid leak may impair gas
exchange and progress to acute respiratory distress syndrome.
Acute kidney injury may result from direct cytokine effects
as well as damage to the microvasculature or reduced tissue
perfusion and hepatic effects may further impair a dysregulated
coagulation system (15, 17). In the brain, inflammatory
mediators, hypoxia, and hypotension may all contribute to
the evolution of encephalopathy. Blood dyscrasias are also
common, with mechanisms not fully understood. It may be
that the expansion in haematopoietic stem cells secondary to
demand and the inflammatory state may actually lead to the
production of dysfunctional stem cells, paradoxically leading to
production of less mature cells like neutrophils (and subsequent
neutropenia) (18).
The dysregulated immune response to infection is
unpredictable, leading to a wide spectrum of clinical
presentations, and time-course for the disease. Multiple
attempts have been made to describe the clinical effects in a
simplified manner that allows early recognition of the septic
patient. Perhaps most notably with the concept of the systemic
inflammatory response syndrome (19). The use of clinical signs
(fever or hypothermia, tachycardia, tachypnoea) and readily
available investigations (high or low white cell count) to identify
patients with this complex physiology in as simple a manner
as possible is attractive. However, the lack of specificity of the
SIRS criteria to identify sepsis specifically and the prevalence
of cases of sepsis that do not meet these criteria make it an
imperfect diagnostic tool (20–22). This lack of specificity may
well-contribute to the high prevalence of antibiotic prescriptions
in hospitals and the ICU (9, 10).
DIAGNOSING SEPSIS
In an attempt to address some of the limitations of the SIRS
criteria and accompanying definitions of sepsis, a new consensus
definition for sepsis was proposed in 2016—life threatening
organ dysfunction caused by infection (16). Organ dysfunction
was defined as an increase in sequential organ failure assessment
(SOFA) score of 2 or more points. Whilst this definition may
increase the sensitivity of diagnosing sepsis and identify those
with the greatest mortality risk, it remains non-specific and has
not been universally adopted (23, 24). Sepsis remains a challenge
to diagnose. The search for a specific biomarker in sepsis is
yet to yield success, despite hundreds of potential molecules
being identified (25–27). Blood cultures are often cited as a gold
standard method of identifying pathogens, but the test remains
flawed in its utility in managing the early stages of sepsis given
the long turn-around time and frequency of contaminated and
false-positive/negative samples (28). Clinicians must therefore
use signs, symptoms and supportive investigations to identify or
suspect infection. This may be straightforward in the coughing,
hypoxic patient with lobar consolidation identified on a chest
radiograph or challenging in an elderly patient for whom
dementia contributes to non-specific symptoms. Supportive
signs and investigations like temperature, white cell count and
inflammatory biomarkers like C-reactive protein or procalcitonin
may be raised in any stress response and early antibiotics, whilst
important for treatment, may impair the identification of a
pathogen from samples cultured after administration.
THERAPIES
The decision on where to treat a person who has sepsis will
largely depend on local hospital resources and the mode and
route of presentation. Many cases will present to the emergency
department directly but management of cases identified in
the community or in hospital inpatients merit consideration.
Regardless of the route to identification of a case, consensus
remains that early treatment of the infection and provision of
supportive care improves outcome (24, 29, 30).
Antimicrobials
The most recent surviving sepsis guidelines recommend
administration of intravenous antimicrobials within 1 h of
identification of sepsis (29). This recommendation is supported
by multiple observational studies that show an association
between delay in antimicrobial administration and increase
in mortality (30–32). Choice of antimicrobial should be
directed to provide coverage for the most likely pathogen
that has caused the septic state. Mirroring the heterogeneity
of the clinical presentation of sepsis, the range of possible
pathogens is myriad and will be dependent on the patient,
their presentation and previous medical history alongside local
factors such as antimicrobial resistance patterns. Given this
heterogeneity and the fact that pathogens are not usually
identified at the time of diagnosis of sepsis, it is not possible
to recommend a specific antibiotic or antibiotic combinations.
Broad-spectrum coverage is usually therefore necessary, with
choice of drug(s) directed at potential site of infection and
coverage of risk factors. This may require the use of multiple
agents, for example the combination of broad spectrum ß-
lactam with vancomycin where MRSA is suspected and addition
of antifungals where invasive fungal disease may be present
(for example where immunocompromised state exists). Choice
of agent should be taken in line with local prescribing
guidelines. Dose andmode of antibiotic administration continues
to evolve in the management of sepsis. The one-size fits
all dosing strategy used in the management of community
infection cannot hold in the management of sepsis where
profound alterations to antimicrobial pharmacokinetics are
likely secondary to both organ dysfunction and changes in
volume of distribution from altered volume status (secondary
to the disease and fluid resuscitation in its management)
Frontiers in Medicine | www.frontiersin.org 2 December 2020 | Volume 7 | Article 588863
Lonsdale et al. Sepsis: Mechanisms and Therapy
TABLE 1 | Commonly used antibiotics and the
pharmacokinetic-pharmacodynamic index associated with therapeutic success.






Table adapted from Roberts and Lipman (37) and Asin-Prieto et al. (38). CMAX , maximum
concentration; MIC, minimum inhibitory concentration of suspected pathogen; T, time;
AUC, area under the time-concentration curve.
(29, 33). Whilst organ dysfunction associated with sepsis can
lead to accumulation of antimicrobials, this is not universal.
Altered antimicrobial pharmacokinetics in sepsis has been shown
to reduce plasma concentration to below levels considered
therapeutic (34, 35) and failure to achieve therapeutic plasma
concentrations has been associated with failure of therapy
(36). It is therefore recommended that dose and frequency
of administration are considered and individualized from
the outset of treatment. These considerations should include
the pharmacokinetic-pharmacodynamic relationship between
antimicrobial and pathogen (Table 1) such that dose and dosing
regimen are optimized. For example, the pharmacokinetic-
pharmacodynamic index associated with successful bacterial kill
of ß-lactams is time with drug concentration above the minimum
inhibitory concentration of the target bacteria. Frequent (and
adequate) dosing is therefore required tomaintain an appropriate
concentration time profile for ß-lactams. A phase III clinical
trial is ongoing into the utility of continuous infusions (39).
Completely individualized treatment courses are difficult to
achieve without rapid therapeutic drug monitoring, which is
often not routinely available, save perhaps for the monitoring for
harm of aminoglycosides. Duration of therapy should minimize
exposure to broad-spectrum antibiotics where possible. This
should include switching to narrow spectrum agents where
pathogens and susceptibility are identified and minimizing the
duration of multi-agent regimens by, for example, reducing
to single agent cover as shock resolves and there is clinical
improvement. Stewardship of antimicrobials in this way will
minimize the potential for emergence of resistant pathogens.
Indeed, such stewardship should be considered as important a
place in therapy as initial choice and dose of antibiotics, since
infection with multi-drug resistant pathogens is associated with
increased hospital length of stay and mortality (40, 41) and
alteration in commensal microbiome to resistant pathogens is
rapid—as quickly as within 1 day of exposure to imipenem in one
study (42).
Source Control
Where sepsis is caused by a focus of infection that is amenable
to source control through surgical or other intervention (e.g.,
removal of infected indwelling catheters), source control should
occur as quickly as practical (within 6–12 h) (43–46).
Fluid Therapy
Whilst there are few clinicians who would advocate removing
fluids from the armory of sepsis management, the choice,
amount and rate of administration of fluid remains controversial
and it is an area of need for ongoing research. The principle
of restoring a circulating volume to provide adequate tissue
perfusion in the vasodilated and fluid shifting septic state
is sound, but for some patients with sepsis cardiac output
may be elevated and tissue blood flow may be increased and
oxygen delivery satisfactory. The one size fits all fluid dose of
30 ml/kg recommended in the most recent surviving sepsis
guidelines is, therefore, controversial. Indeed, by the guide’s own
acknowledgment the evidence to support this recommendation
is “low quality” (29) and there is evidence of harm of over
resuscitation in some settings (5, 47). A gold standard guide to
adequacy of resuscitative volume does not exist. Raised serum
lactate, whilst associated with worse outcomes in sepsis, may
be elevated in the setting of catecholamines (endogenous or
exogenous), hepatic failure, or altered cellular metabolism in
sepsis (29, 48). It is therefore an imperfect guide to volume state.
Indeed, a recent trial found no difference in mortality outcome
between septic patients in whom fluid resuscitation targeted
lactate normalization vs. normal capillary refill time (49). It
would seem prudent, as with recommendations on antimicrobial
and vasopressor administration, that fluid dosing in sepsis
should be personalized. This entails the use of small bolus fluid
administration (250–500mL) with frequent reassessment. The
perfect assessment modality does not exist, simple measures like
capillary refill time or straight leg raise tests may well be as useful
as more complex or invasive assessment modalities such as point
of care ultrasound or haemodynamic monitoring software.
Crystalloids infusions are favored over albumin and synthetic
colloids as the initial fluid of choice, although there is insufficient
evidence to guide choice of crystalloid in sepsis. Balanced
solutions are often preferred to high chloride (0.9% sodium
chloride) infusions but direct head to head trials in sepsis
are missing. Albumin may be considered as a fluid choice,
but high-quality evidence of benefit over crystalloids is lacking
(29, 50, 51).
Target Blood Pressure
A target mean arterial pressure has of 65 mmHg has been
advocated in sepsis (29). This target is based on the principal
of reduced tissue perfusion with lower pressures. Trials of
higher target mean arterial pressure have not shown clinically
meaningful benefit and some evidence of harm from adverse
drug effects (52–54). However, it may be that a lower target is
acceptable. In the recently published “65-trial,” a lower target
mean arterial pressure of 60 mmHg was tested against the 65
mmHg clinical standard in older (over-65) critically ill patients
with vasodilatory shock (55). There was no mortality difference
shown between the two targets. The results of this study has been
cited as supporting personalisation of pressure targets, accepting
lower bound of 60 mmHg in some instances (56), although this
has not been adopted in the recent COVID-19 interim guidance
issued by the surviving sepsis group (57).
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Vasopressors
Norepinephrine is generally accepted as the first-line vasoactive
agent in fluid-refractory septic shock in adults (29), with the
therapeutic aim of restoring mean arterial pressure and tissue
perfusion. Superiority of norepinephrine over dopamine has
been demonstrated in systematic reviews, both in terms of
survival outcome and reduced adverse effects (58, 59). The
surviving sepsis continue to include a recommendation for
the use of dopamine as an alternative in select patients with
low risk of tachyarrhythmias, although the guidelines do not
make recommendations on how to select these patients (29).
Vasopressin may be considered as a second line agent in
vasodilatory shock that persists despite norepinephrine. There is
no mortality benefit of one drug above the other and vasopressin
is probably best considered norepinephrine sparing (29, 60, 61).
Data guiding the norepinephrine dose at which a second agent
should be instituted is lacking. The surviving sepsis authors
advocate an upper dose limit of 0.03 units/min of vasopressin,
this was the dose used in the intervention arm of the VASST trial
(61). The more recent VANISH trial used an upper limit of 0.06
units/min but showed numerically higher incidence of digital
and mesenteric ischaemia compared with norepinephrine doses
(60). Epinephrine is an alternative second line agent. For the
subset of patients with myocardial impairment and low cardiac
output secondary to sepsis, the surviving sepsis guidelines suggest
considering dobutamine as an inotrope.
Other Potential Therapies
A plethora of additional agents have been advocated as tools
in the armory for the treatment of sepsis and shock associated
with sepsis. Corticosteroids, immunoglobulins, vitamin C (with
or without thiamine) are some more common recent examples.
None have been shown to provide meaningful mortality benefit
in high quality randomized controlled trials. Corticosteroids
retain a place for those with adrenal insufficiency (chronic steroid
use, Addison’s disease etc.). Some also advocate corticosteroid
use (200 mg/day for 7-days) in septic shock refractory to fluid
and vasopressor therapy, citing shorter time to resolution of
shock and shorter ICU stay (62, 63). There does not appear to
be a risk of increased secondary infection with this approach,
although hyperglycaemia and hypernatraemia are more common
with steroid use (63). Multiple trials investigating the effect of
vitamin C in sepsis are ongoing.
Supportive ICU Care
Septic patients should receive standard ICU care bundles that
include venous thromboembolism and stress ulcer prophylaxis,
glucose control and sedation care for ventilated patients.
CONCLUSION AND FUTURE WORK
Sepsis remains a challenging condition to manage. Heterogeneity
of presentation, similarity to other inflammatory states
and disease time-course makes diagnosis challenging
and mortality remains high despite global efforts in
improving treatment. International collaboration has been
extraordinary and provides a good starting point for
management. Treatment recommendations are not without
controversy and are probably best used as a platform
to design personalized treatment regimens, rather than
rigidly sticking to protocols. Ongoing work must focus on
improved diagnostics, alongside novel therapeutics. The
need for an sensitive and specific biomarker seems most
pressing, as it would enable appropriate management for
the individual patient, assist in antimicrobial stewardship
to protect drugs for the population and provide the ability
to more accurately recruit participants with true sepsis to
interventional trials.
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